News & Events about Kinnate Biopharma Inc.
Kinnate Biopharma Inc. (NASDAQ:KNTE Get Rating) Director Carl L. Gordon purchased 350,749 shares of the businesss stock in a transaction on Friday, April 28th. The stock was acquired at an average price of $2.55 per share, with a total value of $894,409.95. Following the completion of...
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the ...
JPMorgan Chase & Co. increased its stake in Kinnate Biopharma Inc. (NASDAQ:KNTE) by 60.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,147 shares of the companys stock after acquiring an additional 3,079 shares during the period. JPMorgan Chase...